Univ Lyon, Université Claude Bernard Lyon 1, CNRS, INSA Lyon, Ecole Centrale de Lyon, CPE Lyon, INL, UMR5270, 69622 Villeurbanne, France.
Institut Lumière Matière ILM-UMR 5306, CNRS, Université Lyon 1, 69622 Villeurbanne, France.
Int J Mol Sci. 2022 Feb 10;23(4):1981. doi: 10.3390/ijms23041981.
The selection of circulating tumor cells (CTCs) directly from blood as a real-time liquid biopsy has received increasing attention over the past ten years, and further analysis of these cells may greatly aid in both research and clinical applications. CTC analysis could advance understandings of metastatic cascade, tumor evolution, and patient heterogeneity, as well as drug resistance. Until now, the rarity and heterogeneity of CTCs have been technical challenges to their wider use in clinical studies, but microfluidic-based isolation technologies have emerged as promising tools to address these limitations. This review provides a detailed overview of latest and leading microfluidic devices implemented for CTC isolation. In particular, this study details must-have device performances and highlights the tradeoff between recovery and purity. Finally, the review gives a report of CTC potential clinical applications that can be conducted after CTC isolation. Widespread microfluidic devices, which aim to support liquid-biopsy-based applications, will represent a paradigm shift for cancer clinical care in the near future.
过去十年中，直接从血液中选择循环肿瘤细胞（CTC）作为实时液体活检已受到越来越多的关注，对这些细胞的进一步分析可能会极大地促进研究和临床应用。CTC 分析可以增进对转移级联、肿瘤进化和患者异质性以及耐药性的理解。到目前为止，CTC 的稀有性和异质性一直是其在临床研究中广泛应用的技术挑战，但基于微流控的分离技术已成为解决这些限制的有前途的工具。本综述详细介绍了最新的领先的微流控设备，用于 CTC 分离。特别是，本研究详细说明了必备的设备性能，并强调了回收率和纯度之间的权衡。最后，该综述报告了 CTC 分离后可以进行的潜在临床应用。旨在支持液体活检应用的广泛应用的微流控设备将代表癌症临床护理在不久的将来的范式转变。
